Specification :

AFP-L3 is recognized as a new generation of liver cancer markers in the diagnosis, its main characteristics are:

1) Compared with imaging technology, the alpha fetoprotein heteroplasmon AFP-L3 can be detected earlier 9-12 months. When AFP L3 accounting for more than 10% in the gross of AFP, it suggested that the incidence of liver carcinoma is greater than 95%. Eliminating the limit of the negative results for the imaging examination can be helpful to identify the liver space-occupying lesions which are difficult to diagnose with imaging examination.

2) This method has no limit that AFP e 400ng / ml is taken as the liver cancer diagnosis criteria, also, it needn’t take the dynamic observation for AFP content change, thereby shortening the time for the diagnosis of liver carcinoma.

3) Moreover, AFP-L3 has important significance in the assessment of effect and on prompting the recurrence of liver cancer; also, it is very helpful to the assessment of the malignant degree of tumor and tumor treatment options.

4) This method had been used in clinical testing in Japan for many years. FDA of the United States has ratified the biomarkers on October 2005 to use in clinical field and it marked the markers of liver cancer will be used in the world.